These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27349496)

  • 1. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.
    Kiwata JL; Dorff TB; Schroeder ET; Gross ME; Dieli-Conwright CM
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):323-332. PubMed ID: 27349496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
    BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
    PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
    Foulkes SJ; Daly RM; Fraser SF
    Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
    Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
    Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.
    Kiwata JL; Dorff TB; Todd Schroeder E; Salem GJ; Lane CJ; Rice JC; Gross ME; Dieli-Conwright CM
    BMJ Open; 2017 Jul; 7(7):e016910. PubMed ID: 28698349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.
    Saylor PJ; Smith MR
    J Natl Compr Canc Netw; 2010 Feb; 8(2):211-23. PubMed ID: 20141678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training.
    Mundell NL; Daly RM; Macpherson H; Fraser SF
    Endocr Relat Cancer; 2017 Apr; 24(4):R145-R155. PubMed ID: 28209634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of multidisciplinary interventions in preventing metabolic syndrome and improving body composition in prostate cancer patients treated with androgen deprivation therapy: A systematic review and meta-analysis.
    Yang U; Harikrishna A; Preda V; Chen J
    Clin Nutr ESPEN; 2023 Dec; 58():27-49. PubMed ID: 38057016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trial.
    Focht BC; Lucas AR; Grainger E; Simpson C; Thomas-Ahner JM; Clinton SK
    Trials; 2014 Sep; 15():354. PubMed ID: 25199619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients.
    Urushima H; Inomata-Kurashiki Y; Nishimura K; Sumi R; Shimomura I; Nonomura N; Ito T; Maeda K
    Aging Male; 2015 Jun; 18(2):72-6. PubMed ID: 25746209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.
    Collins L; Basaria S
    Asian J Androl; 2012 Mar; 14(2):222-5. PubMed ID: 22343494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.
    Tzortzis V; Samarinas M; Zachos I; Oeconomou A; Pisters LL; Bargiota A
    Hormones (Athens); 2017 Apr; 16(2):115-123. PubMed ID: 28742500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
    Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
    Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.